Group 1 - The core viewpoint of the article highlights the recovery of the primary market in Jiangsu, with a significant increase in private equity financing events, totaling over 530 in the first half of the year, indicating a strong preference for "hard technology" sectors and a rational return to early-stage investments [1][2] Group 2 - Advanced manufacturing and healthcare are the two favored sectors, accounting for over half of the total financing events in Jiangsu, with 270 occurrences in the first half of the year [2] - Notable investments include Jiushi Intelligent's $100 million B3 round financing, marking the largest single round in the autonomous driving sector in nearly two years, with a total of nearly $300 million raised in B rounds [2] - NuoLing Bio completed a multi-hundred million C round financing, focusing on portable inhalation therapy devices for cardiovascular treatment, which have been deployed in hundreds of hospitals [3] Group 3 - The trend of "investing early and small" has become mainstream, with early-stage investments (seed, angel, Pre-A, A rounds) accounting for nearly 60% of total investment events in Jiangsu [4] - Yanwei Semiconductor, established in 2022, has completed four rounds of financing totaling nearly 1 billion yuan, showcasing the effectiveness of early-stage funding [4] Group 4 - The "+ round" investment model is increasingly common, allowing companies to secure additional funding within the same round, which helps alleviate cash flow pressures and allows investors to manage risks more effectively [5] Group 5 - The Jiangsu mother fund has emerged as a strong engine for the growth of the venture capital market, with a total scale of 500 billion yuan and the establishment of 41 specialized funds within a year, covering all 13 districts in the province [7][8] - Various cities in Jiangsu are employing a combination of "one mother fund + several sub-funds" to target their key industries, resulting in a fast-paced and high-density investment environment [7] Group 6 - Recent regulatory innovations, such as the revised management measures for the Jiangsu strategic emerging industry mother fund, have facilitated collaboration with central enterprises and social security funds, broadening the scope for industry-specific fund applications [8] - The mother fund system has already invested in 86 projects, focusing on "hard technology" sectors, with the potential for further aggregation effects as more specialized funds are launched [8]

报名：首届全球眼科大会 | 议程更新 报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 合作伙伴征集：2025全球手术机器人大会 近日， 南京诺令生物科技有限公司 （简称"诺令生物"）宣布完成 数亿元人民币C轮融资 。本轮融资由鼎信资本领投，扬州国金集团、中山金控、勤智资本、倚锋资本和兴湘资本等多家知名机 构共同参与投资。熙桥资本担任本轮融资的独家财务顾问。所获资金将主要用于 ，同时加速基于NO缓释和发生技术的创新管线落地。 $$\#\nrightarrow\mp{\frac{1}{12}}\otimes\nrightarrow\pm{\frac{1}{12}}$$ 诺令生物于2018年4月在南京成立，是国内首家、全球领先的专注于 气体诊疗 的创新型医疗器械企业。公司拥有一支业内顶尖的技术和产品开发团队，掌握国际领先的分子技术平 台，涵盖化学、机械、材料、算法和传感等跨学科领域。 公司以 自主研发的一氧化氮即时发生及缓释控制分子技术平台（NOGMT） 为立足点， 致力于解决心肺、呼吸、抗感染等领域重大临床痛点，为气体检测及治疗领域提供突破性临床解决方 案。 公司首款核心产品"便携式 ...